# Lipid Formulation to Increase the Bioavailability of Fatty Acids in Cystic Fibrosis (CF) Patients

> **NCT02646995** · NA · COMPLETED · sponsor: **Société des Produits Nestlé (SPN)** · enrollment: 16 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DIETARY_SUPPLEMENT:** modified lipid formulation
- **DIETARY_SUPPLEMENT:** Fish oil

## Key facts

- **NCT ID:** NCT02646995
- **Lead sponsor:** Société des Produits Nestlé (SPN)
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2017-03-27
- **Final completion:** 2017-05-04
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02646995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02646995, "Lipid Formulation to Increase the Bioavailability of Fatty Acids in Cystic Fibrosis (CF) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02646995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*